| Latest Napo Pharm.Regs News Headlines |
| Date | Time | Source | |
| 10/15/2008 | 1:38PM | TFNF | Napo Pharma raises $1 mln with convertible debt issue
Napo Pharmaceuticals Inc. said that, as part of
its ongoing fundraising activities, it has raised approximately $1 million
through the issue of convertible debt.
The Notes are repayable on June 20 2009 and bear interest at 8 percent per
annum.
tf.TFN-Europe_newsdesk@thomsonreuters.com
slm
COPYRIGHT
Copyright... More...>> |
| 10/15/2008 | 1:14PM | UKREG | Fundraising
RNS Number : 9604F
Napo Pharmaceuticals Inc
15 October 2008
For immediate release 15 October 2008
Napo Pharmaceuticals, Inc
("Napo" or "the Company")
Fundraising
South San Francisco, California, 15 October, 2008 - Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU), is pleased... More...>> |
| 10/03/2008 | 7:21AM | UKREG | Fundraising
RNS Number : 0540F
Napo Pharmaceuticals Inc
03 October 2008
For immediate release 3 October 2008
Napo Pharmaceuticals, Inc
("Napo" or "the Company")
FUNDRAISING
South San Francisco, California, 3 October, 2008 - Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU), is pleased... More...>> |
| 10/03/2008 | 3:07AM | TFNF | BRIEF-Napo pharma Inc debt issue raised about $500,000
LONDON, Oct 3 (Reuters) - NAPO:
* Napo pharma inc says has raised approximately US$500,000 through the issue
of
convertible debt
* At a meeting of the Company's shareholders on 17 September 2008
shareholders approved the delisting of the Company from the Official List of the
London Stock Exchange... More...>> |
| 10/03/2008 | 2:00AM | RNSNON | Fundraising
RNS Number : 0055F
Napo Pharmaceuticals Inc
03 October 2008
For immediate release 3 October 2008
Napo Pharmaceuticals, Inc
("Napo" or "the Company")
FUNDRAISING
South San Francisco, California, 3 October, 2008 - Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU), is pleased... More...>> |
| 09/25/2008 | 12:58PM | RNSNON | Pediatric Formulation of Crofelemer
RNS Number : 3715E
Napo Pharmaceuticals Inc
25 September 2008
For immediate release 25 September 2008
Napo Pharmaceuticals, Inc
("Napo" or "the Company")
NAPO PHARMACEUTICALS will provide pediatric Formulation Of crofelemer At Cost to developing nations to Help Treat... More...>> |
| 09/22/2008 | 9:07AM | RNSNON | Positive Clinical Data
RNS Number : 9838D
Napo Pharmaceuticals Inc
22 September 2008
For immediate release 22 September 2008
Napo Pharmaceuticals, Inc
("Napo" or "the Company")
Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera
South San Francisco... More...>> |
| 09/19/2008 | 11:10AM | TFNF | Napo Pharma in venture to provide Crofelemer to children in disaster areas
Napo Pharmaceuticals Inc. said it and Direct
Relief International ("DRI") of Santa Barbara, California have linked up to
provide a development stage pharmaceutical product to pediatric populations in
disaster situations and resource-constrained geographies, termed the Crofelemer
Access Program ("CAP"). Crofelemer... More...>> |
| 09/19/2008 | 10:13AM | RNSNON | Development Alliance
RNS Number : 8832D
Napo Pharmaceuticals Inc
19 September 2008
For immediate release 19 September 2008
Napo Pharmaceuticals, Inc
("Napo" or "the Company")
NOVEL DRUG DEVELOPMENT ALLIANCE BETWEEN NAPO pHARMACUETICALS AND DIRECT RELIEF INTERNATIONAL TARGETS GLOBAL IMPLICATIONS OF... More...>> |
| 09/18/2008 | 3:47AM | TFNF | Napo Pharma shareholders approve LSE de-listing; stock split
Napo Pharmaceuticals Inc. said its shareholders
have approved the de-listing of the company's shares from the London Stock
Exchange.
It is anticipated trading in the company's shares will cease at the close of
business on Oct. 15, Napo added.
Napo Pharma said the shareholders also approved a reverse... More...>> |
| 09/18/2008 | 2:01AM | UKREG | Results of Special Meeting
RNS Number : 7117D
Napo Pharmaceuticals Inc
18 September 2008
For immediate release 18 September 2008
Napo Pharmaceuticals, Inc
("Napo" or "the Company")
Results of Special Meeting of Stockholders
South San Francisco, California, 18 September 2008 - Napo Pharmaceuticals, Inc... More...>> |
| 09/15/2008 | 10:39AM | TFNF | Napo Pharma says raises $200,000 via convertible debt issue
Napo Pharmaceuticals Inc. said it raised around
$200,000 as part of its fundraising campaign via issue of convertible debt,
repayable in cash or shares on June 20, 2009.
The proceeds together with existing resources and other funds will go
towards financing working capital needs and continue to finance the... More...>> |
| 09/15/2008 | 10:09AM | UKREG | Fundraising
RNS Number : 4648D
Napo Pharmaceuticals Inc
15 September 2008
For immediate release 15 September 2008
Napo Pharmaceuticals, Inc
("Napo" or "the Company")
Fundraising
South San Francisco, California, 15 September, 2008 - Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU), is pleased... More...>> |
| 09/05/2008 | 11:42AM | TFNF | Napo Pharma in deal for Crofelemer commercialization UPDATE
(Recasts, update to add the funds requirement)
Napo Pharmaceuticals Inc. said it has signed a
non-legally binding term sheet with an unnamed pharmaceutical company for the
commercialization in North America and Mexico of Crofelemer for the indication
of chronic diarrhoea in persons living with HIV/AIDS (CRO-HIV... More...>> |
| 09/05/2008 | 11:17AM | TFNF | Napo Pharma to seek delisting; in deal for Crofelemer commercialization
Napo Pharmaceuticals Inc. said it has sent a
circular to shareholders setting out details of a proposed delisting and
cancellation of the company's shares.
The circular also includes the adoption of new bylaws to eliminate
pre-emptive rights, authorization of an increase in the share capital and
authorizing... More...>> |
| 09/05/2008 | 10:44AM | UKREG | Delisting Circular
RNS Number : 8760C
Napo Pharmaceuticals Inc
05 September 2008
The Delisting Circular announcement for Napo Pharmaceuticals Inc released on 5 September 2008 at 15:41 under RNS No 8756C has been
re-released to facilitate onward
transmission by third party vendors.
The announcement is unchanged and is... More...>> |
| 09/05/2008 | 10:38AM | UKREG | Delisting Circular
RNS Number : 8756C
Napo Pharmaceuticals Inc
05 September 2008
For immediate release 5 September 2008
Napo Pharmaceuticals, Inc
("Napo" or "the Company")
Proposed delisting and cancellation of the Company's Listing and posting of a Circular and Notice of Special Meeting of Shareholders... More...>> |
| 08/29/2008 | 4:33AM | TFNF | Napo Pharmaceuticals H1 loss widens as co says funding essential to survive
Napo Pharmaceuticals Inc. reported deepening
losses for the first half of 2008 and said that, unless it raises more funds,
its future is in jeopardy.
The group, which focuses on bringing proprietary products to the global
marketplace in collaboration with local partners, saw its net loss widen in the
first... More...>> |
| 08/29/2008 | 2:04AM | UKREG | Interim Results
RNS Number : 2727C
Napo Pharmaceuticals Inc
29 August 2008
For immediate release 29 August 2008
Napo Pharmaceuticals, Inc
("Napo" or "the Company")
Interim Results for the Six Months Ended 30 June 2008
South San Francisco, California, 29 August 2008 - Napo Pharmaceuticals... More...>> |
| 07/10/2008 | 12:04PM | TFNF | Napo Pharma says Crofelemer trials show improvement for female patients
Napo Pharmaceuticals Inc. said data analysis of
the dose-ranging phase 2 study in diarrhoea predominant irritable bowel syndrome
(D-IBS) patients indicates Crofelemer at a dose of 500 mg twice daily, helped
female D-IBS patients.
Chief executive Lisa Conte said due to the improvement in pain-free days,
the... More...>> |